In essential thrombocythemia patients alpha-IFN rapidly reduces platelet count, and it is also able to maintain a low count during long-term treatment. In order to verify if long-term IFN treatment can produce sustained remission in selected patients, we decided to suspend IFN treatment in two subsets of 21 patients on long-term alpha-IFN treatment: (a) all six patients who had shown a platelet count below 450 x 10(9)/l for at least 2 months with 3 MU once a week; (b) three patients who had shown the same platelet count for at least 2 months with 3 MU three times a week. After withdrawal of alpha-IFN treatment, a rapid increase in the platelet count was observed in all three patients requiring 3 MU three times a week. Three of the six patients treated with 3 MU once a week are still free of symptoms and have been in complete hematological remission (platelet count below 450 x 10(9)/l) for 9+, 13+, and 14+ months, respectively. As far as the three remaining cases are concerned, one was not assessable because of loss to follow-up, while the other two relapsed after 1 and 2 months. We believe that the three cases of sustained remission might be the result of a long-term tumor load reduction produced by the alpha-IFN treatment. Finally, the factor best able to predict sustained, unmaintained remission seems to be the clinical response to a low dose of alpha-IFN during the maintenance phase, rather than disease features prior to treatment.

Sustained complete hematological remission in essential thrombocythemia after discontinuation of long-term alpha-IFN treatment / Sacchi, Stefano; Tabilio, A; Leoni, P; Riccardi, A; Vecchi, A; Messora, C; Bensi, L; Falzetti, F; Rupoli, S; Ucci, G.. - In: ANNALS OF HEMATOLOGY. - ISSN 0939-5555. - STAMPA. - 66:(1993), pp. 245-246.

Sustained complete hematological remission in essential thrombocythemia after discontinuation of long-term alpha-IFN treatment

SACCHI, Stefano;
1993

Abstract

In essential thrombocythemia patients alpha-IFN rapidly reduces platelet count, and it is also able to maintain a low count during long-term treatment. In order to verify if long-term IFN treatment can produce sustained remission in selected patients, we decided to suspend IFN treatment in two subsets of 21 patients on long-term alpha-IFN treatment: (a) all six patients who had shown a platelet count below 450 x 10(9)/l for at least 2 months with 3 MU once a week; (b) three patients who had shown the same platelet count for at least 2 months with 3 MU three times a week. After withdrawal of alpha-IFN treatment, a rapid increase in the platelet count was observed in all three patients requiring 3 MU three times a week. Three of the six patients treated with 3 MU once a week are still free of symptoms and have been in complete hematological remission (platelet count below 450 x 10(9)/l) for 9+, 13+, and 14+ months, respectively. As far as the three remaining cases are concerned, one was not assessable because of loss to follow-up, while the other two relapsed after 1 and 2 months. We believe that the three cases of sustained remission might be the result of a long-term tumor load reduction produced by the alpha-IFN treatment. Finally, the factor best able to predict sustained, unmaintained remission seems to be the clinical response to a low dose of alpha-IFN during the maintenance phase, rather than disease features prior to treatment.
1993
66
245
246
Sustained complete hematological remission in essential thrombocythemia after discontinuation of long-term alpha-IFN treatment / Sacchi, Stefano; Tabilio, A; Leoni, P; Riccardi, A; Vecchi, A; Messora, C; Bensi, L; Falzetti, F; Rupoli, S; Ucci, G.. - In: ANNALS OF HEMATOLOGY. - ISSN 0939-5555. - STAMPA. - 66:(1993), pp. 245-246.
Sacchi, Stefano; Tabilio, A; Leoni, P; Riccardi, A; Vecchi, A; Messora, C; Bensi, L; Falzetti, F; Rupoli, S; Ucci, G.
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/618582
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 17
  • ???jsp.display-item.citation.isi??? 13
social impact